218 is the total number of securities NEXTHERA CAPITAL LP has owned. The longest NEXTHERA CAPITAL LP has owned a single stock is 13 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| INSM | Insmed Inc | 9 | 4 | 0.52% | 3.44% | 10.04% | Q1 2016 | Q2 2019 | 13 |
| GBT | Global Blood Therapeut... | 11 | 11 | 0.51% | 3.43% | 6.23% | Q4 2016 | Q2 2019 | 11 |
| SHPG | Shire PLC | 9 | 9 | 2.74% | 8.19% | 13.57% | Q1 2016 | Q1 2018 | 9 |
| IMMU | Immunomedics Inc | 8 | 1 | 1.20% | 4.31% | 7.80% | Q3 2016 | Q2 2019 | 9 |
| AGN | Allergan PLC | 4 | 2 | 0.47% | 4.91% | 7.64% | Q4 2015 | Q2 2019 | 8 |
| FGEN | FibroGen Inc | 5 | 3 | 0.59% | 1.63% | 3.01% | Q2 2016 | Q3 2018 | 8 |
| ABEO | Abeona Therapeutics Inc | 5 | 3 | 0.20% | 1.22% | 2.08% | Q2 2016 | Q3 2018 | 8 |
| PFE | Pfizer Inc | 7 | 7 | 5.12% | 12.30% | 19.10% | Q4 2015 | Q2 2017 | 7 |
| SGEN | Seattle Genetics Inc | 4 | 1 | 1.05% | 3.98% | 5.73% | Q4 2015 | Q2 2018 | 7 |
| MYL | Mylan NV | 4 | 1 | 1.63% | 3.73% | 6.53% | Q1 2016 | Q2 2019 | 7 |
| CBAY | Cymabay Therapeutics Inc | 7 | 7 | 0.03% | 1.73% | 3.39% | Q3 2017 | Q1 2019 | 7 |
| NERV | Minerva Neurosciences Inc | 4 | 3 | 0.22% | 1.61% | 3.40% | Q4 2015 | Q3 2017 | 7 |
| ADXS | Advaxis Inc | 7 | 7 | 0.40% | 0.84% | 1.31% | Q4 2015 | Q2 2017 | 7 |
| VTGN | VistaGen Therapeutics Inc | 7 | 7 | 0.03% | 0.21% | 0.47% | Q2 2016 | Q4 2017 | 7 |
| XBI | SPDR S&P Biotech ETF | 6 | 6 | 14.76% | 26.03% | 33.40% | Q3 2017 | Q4 2018 | 6 |
| DOVA | Dova Pharmaceuticals Inc | 6 | 6 | 1.92% | 2.92% | 4.13% | Q2 2017 | Q3 2018 | 6 |
| IMDZ | Immune Design Corp | 5 | 1 | 0.03% | 0.83% | 1.42% | Q4 2015 | Q3 2018 | 6 |
| CELG | Celgene Corp | 3 | 2 | 5.61% | 9.82% | 14.00% | Q4 2015 | Q2 2017 | 5 |
| GSK | GlaxoSmithKline PLC | 3 | 2 | 3.74% | 8.68% | 17.64% | Q2 2016 | Q3 2017 | 5 |
| BOLD | Audentes Therapeutics Inc | 5 | 5 | 1.43% | 6.68% | 11.87% | Q2 2018 | Q2 2019 | 5 |
| BMRN | BioMarin Pharmaceutica... | 5 | 5 | 1.44% | 5.01% | 11.98% | Q4 2017 | Q4 2018 | 5 |
| ALXN | Alexion Pharmaceutical... | 4 | 1 | 2.25% | 4.74% | 7.17% | Q4 2016 | Q2 2018 | 5 |
| HRTX | Heron Therapeutics Inc | 3 | 1 | 0.54% | 4.72% | 11.53% | Q4 2015 | Q1 2019 | 5 |
| NBIX | Neurocrine Biosciences... | 2 | 1 | 1.72% | 3.14% | 6.50% | Q4 2015 | Q2 2019 | 5 |
| BMRN | BioMarin Pharmaceutica... | 4 | 1 | 0.89% | 2.78% | 3.99% | Q2 2017 | Q1 2019 | 5 |
| STML | Stemline Therapeutics Inc | 5 | 5 | 1.32% | 2.48% | 5.08% | Q1 2018 | Q1 2019 | 5 |
| Neuroderm Ltd | 2 | 1 | 1.02% | 2.37% | 4.26% | Q4 2015 | Q2 2017 | 5 | |
| CNCE | Concert Pharmaceutical... | 5 | 5 | 1.01% | 2.27% | 4.92% | Q4 2015 | Q4 2016 | 5 |
| SGMO | Sangamo Therapeutics Inc | 4 | 1 | 0.90% | 2.17% | 3.01% | Q4 2016 | Q2 2018 | 5 |
| QURE | UniQure NV | 3 | 2 | 0.60% | 1.91% | 3.90% | Q4 2015 | Q2 2019 | 5 |
| CARA | Cara Therapeutics Inc | 3 | 2 | 0.72% | 1.58% | 3.38% | Q4 2016 | Q3 2018 | 5 |
| CBIO | Catalyst Biosciences Inc | 5 | 5 | 0.78% | 1.51% | 2.29% | Q4 2017 | Q4 2018 | 5 |
| RXDX | Ignyta Inc | 3 | 2 | 0.91% | 1.13% | 1.47% | Q1 2016 | Q3 2017 | 5 |
| KURA | Kura Oncology Inc | 5 | 5 | 0.99% | 1.09% | 1.26% | Q3 2017 | Q3 2018 | 5 |
| MRNS | Marinus Pharmaceutical... | 4 | 1 | 0.27% | 0.72% | 1.39% | Q4 2015 | Q4 2017 | 5 |
| MDGL | Madrigal Pharmaceutica... | 2 | 1 | 0.16% | 0.61% | 1.35% | Q3 2017 | Q2 2019 | 5 |
| HZNP | Horizon Pharma PLC | 2 | 1 | 3.19% | 4.03% | 4.74% | Q4 2015 | Q4 2018 | 4 |
| EXEL | Exelixis Inc | 4 | 4 | 2.50% | 3.93% | 5.89% | Q2 2018 | Q1 2019 | 4 |
| AZN | AstraZeneca PLC | 3 | 1 | 1.47% | 2.97% | 4.80% | Q4 2016 | Q3 2018 | 4 |
| ALNY | Alnylam Pharmaceutical... | 3 | 1 | 2.02% | 2.93% | 3.65% | Q4 2016 | Q4 2017 | 4 |
| TSRO | TESARO Inc | 4 | 4 | 0.76% | 2.35% | 3.93% | Q1 2017 | Q4 2017 | 4 |
| ADMS | Adamas Pharmaceuticals... | 4 | 4 | 1.50% | 2.10% | 2.81% | Q1 2016 | Q4 2016 | 4 |
| SAGE | Sage Therapeutics Inc | 3 | 1 | 1.20% | 1.72% | 2.08% | Q4 2017 | Q1 2019 | 4 |
| EIGR | Eiger BioPharmaceutica... | 4 | 4 | 0.24% | 1.44% | 2.17% | Q2 2016 | Q1 2017 | 4 |
| AERI | Aerie Pharmaceuticals Inc | 4 | 4 | 0.76% | 1.14% | 1.68% | Q4 2015 | Q3 2016 | 4 |
| PRTK | Paratek Pharmaceutical... | 4 | 4 | 0.52% | 1.12% | 1.56% | Q4 2016 | Q3 2017 | 4 |
| DCPH | Deciphera Pharmaceutic... | 4 | 4 | 0.23% | 0.82% | 1.21% | Q2 2018 | Q1 2019 | 4 |
| ZSAN | Zosano Pharma Corp | 4 | 4 | 0.44% | 0.63% | 0.81% | Q1 2018 | Q4 2018 | 4 |
| VSTM | Verastem Inc | 4 | 4 | 0.22% | 0.31% | 0.38% | Q2 2016 | Q1 2017 | 4 |
| VBLT | Vascular Biogenics Ltd | 3 | 1 | 0.09% | 0.14% | 0.25% | Q4 2015 | Q1 2017 | 4 |
| BMY | Bristol-Myers Squibb Co | 2 | 1 | 3.57% | 8.17% | 14.25% | Q4 2015 | Q1 2018 | 3 |
| NVS | Novartis AG | 2 | 1 | 4.65% | 8.10% | 11.18% | Q4 2016 | Q1 2019 | 3 |
| AZN | AstraZeneca PLC | 2 | 1 | 2.98% | 6.02% | 7.79% | Q1 2017 | Q4 2017 | 3 |
| BHC | Bausch Health Cos Inc | 3 | 3 | 2.68% | 4.64% | 6.16% | Q3 2018 | Q1 2019 | 3 |
| KITE | Kite Pharma Inc | 3 | 3 | 3.94% | 4.22% | 4.52% | Q4 2016 | Q2 2017 | 3 |
| PCRX | Pacira Pharmaceuticals... | 2 | 1 | 2.46% | 3.56% | 5.40% | Q1 2018 | Q2 2019 | 3 |
| XLRN | Acceleron Pharma Inc | 3 | 3 | 2.66% | 3.47% | 4.84% | Q2 2016 | Q4 2016 | 3 |
| LCI | Lannett Inc | 3 | 3 | 2.73% | 3.42% | 4.74% | Q1 2016 | Q3 2016 | 3 |
| ASND | Ascendis Pharma A/S | 2 | 1 | 1.19% | 2.92% | 5.78% | Q3 2016 | Q2 2019 | 3 |
| ACRS | Aclaris Therapeutics Inc | 3 | 3 | 1.70% | 2.83% | 4.02% | Q1 2017 | Q3 2017 | 3 |
| AQXP | Aquinox Pharmaceutical... | 2 | 1 | 0.56% | 2.07% | 2.86% | Q2 2016 | Q2 2017 | 3 |
| CLVS | Clovis Oncology Inc | 3 | 3 | 0.74% | 1.92% | 2.92% | Q3 2017 | Q1 2018 | 3 |
| TRVN | Trevena Inc | 3 | 3 | 0.82% | 1.14% | 1.38% | Q2 2016 | Q4 2016 | 3 |
| ACOR | Acorda Therapeutics Inc | 2 | 1 | 0.19% | 1.11% | 2.50% | Q2 2018 | Q1 2019 | 3 |
| CHMA | Chiasma Inc | 3 | 3 | 0.44% | 1.03% | 1.37% | Q3 2018 | Q1 2019 | 3 |
| AKRXQ | Akorn Inc | 3 | 3 | 0.09% | 0.78% | 1.55% | Q1 2018 | Q3 2018 | 3 |
| FOMX | Foamix Pharmaceuticals... | 2 | 1 | 0.71% | 0.78% | 0.82% | Q2 2016 | Q3 2018 | 3 |
| PGNX | Progenics Pharmaceutic... | 3 | 3 | 0.35% | 0.72% | 1.36% | Q1 2016 | Q3 2016 | 3 |
| TBRA | Tobira Therapeutics Inc | 3 | 3 | 0.38% | 0.57% | 0.82% | Q4 2015 | Q2 2016 | 3 |
| ONCS | OncoSec Medical Inc | 3 | 3 | 0.37% | 0.52% | 0.64% | Q1 2018 | Q3 2018 | 3 |
| CLSD | Clearside Biomedical Inc | 2 | 1 | 0.21% | 0.44% | 0.63% | Q4 2016 | Q3 2018 | 3 |
| STDY | SteadyMed Ltd | 3 | 3 | 0.02% | 0.41% | 0.99% | Q1 2017 | Q3 2017 | 3 |
| NEOS | Neos Therapeutics Inc | 2 | 1 | 0.29% | 0.32% | 0.37% | Q4 2015 | Q3 2018 | 3 |
| ZSAN | Zosano Pharma Corp | 3 | 3 | 0.08% | 0.27% | 0.48% | Q1 2017 | Q3 2017 | 3 |
| TGTX | TG Therapeutics Inc | 2 | 1 | 0.04% | 0.22% | 0.48% | Q4 2017 | Q3 2018 | 3 |
| MDWD | MediWound Ltd | 3 | 3 | 0.05% | 0.14% | 0.20% | Q2 2018 | Q4 2018 | 3 |
| ICPT | Intercept Pharmaceutic... | 2 | 2 | 1.62% | 5.86% | 10.10% | Q1 2019 | Q2 2019 | 2 |
| MRK | Merck & Co Inc New | 1 | 1 | 3.59% | 5.69% | 7.79% | Q4 2015 | Q4 2017 | 2 |
| URGN | UroGen Pharma Ltd | 2 | 2 | 5.30% | 5.62% | 5.94% | Q1 2019 | Q2 2019 | 2 |
| SRPT | Sarepta Therapeutics Inc | 2 | 2 | 3.08% | 4.72% | 6.37% | Q1 2019 | Q2 2019 | 2 |
| AstraZeneca PLC | 2 | 2 | 4.00% | 4.53% | 5.05% | Q3 2016 | Q4 2016 | 2 | |
| ABBV | AbbVie Inc | 1 | 1 | 3.19% | 4.18% | 5.17% | Q4 2015 | Q2 2019 | 2 |
| AMRN | Amarin Corp PLC | 2 | 2 | 3.72% | 3.73% | 3.75% | Q1 2019 | Q2 2019 | 2 |
| VNDA | Vanda Pharmaceuticals Inc | 2 | 2 | 3.28% | 3.47% | 3.66% | Q1 2017 | Q2 2017 | 2 |
| CLVS | Clovis Oncology Inc | 1 | 1 | 2.66% | 3.29% | 3.92% | Q3 2016 | Q3 2017 | 2 |
| ARRY | Array BioPharma Inc | 2 | 2 | 2.92% | 3.28% | 3.65% | Q1 2017 | Q2 2017 | 2 |
| IPXL | Impax Laboratories Inc | 2 | 2 | 2.10% | 3.02% | 3.93% | Q2 2017 | Q3 2017 | 2 |
| CLLS | Cellectis SA | 2 | 2 | 1.73% | 2.06% | 2.40% | Q1 2018 | Q2 2018 | 2 |
| CYNA | Cynapsus Therapeutics Inc | 2 | 2 | 0.42% | 1.98% | 3.54% | Q1 2016 | Q2 2016 | 2 |
| FLXN | Flexion Therapeutics Inc | 2 | 2 | 1.69% | 1.86% | 2.03% | Q2 2017 | Q3 2017 | 2 |
| ALDR | Alder Biopharmaceutica... | 1 | 1 | 0.84% | 1.83% | 2.81% | Q4 2015 | Q2 2016 | 2 |
| CORT | Corcept Therapeutics Inc | 2 | 2 | 0.82% | 1.82% | 2.83% | Q1 2018 | Q2 2018 | 2 |
| ARRY | Array BioPharma Inc | 1 | 1 | 1.61% | 1.78% | 1.95% | Q2 2016 | Q3 2017 | 2 |
| TSRO | TESARO Inc | 1 | 1 | 0.57% | 1.78% | 2.98% | Q2 2017 | Q2 2018 | 2 |
| ECYT | Endocyte Inc | 2 | 2 | 1.27% | 1.75% | 2.23% | Q2 2018 | Q3 2018 | 2 |
| NLNK | NewLink Genetics Corp | 1 | 1 | 0.60% | 1.53% | 2.46% | Q1 2017 | Q1 2018 | 2 |
| ZGNX | Zogenix Inc | 2 | 2 | 1.07% | 1.45% | 1.83% | Q3 2016 | Q4 2016 | 2 |
| GLYC | GlycoMimetics Inc | 2 | 2 | 1.16% | 1.32% | 1.49% | Q3 2017 | Q4 2017 | 2 |
| DERM | Dermira Inc | 1 | 1 | 1.10% | 1.32% | 1.53% | Q2 2017 | Q2 2019 | 2 |
| LBIO | Lion Biotechnologies Inc | 2 | 2 | 0.80% | 1.23% | 1.67% | Q4 2015 | Q1 2016 | 2 |
| IMGN | ImmunoGen Inc | 2 | 2 | 0.38% | 1.19% | 2.01% | Q1 2016 | Q2 2016 | 2 |
| TXMD | TherapeuticsMD Inc | 1 | 1 | 0.59% | 1.12% | 1.64% | Q4 2017 | Q3 2018 | 2 |
| FPRX | Five Prime Therapeutic... | 2 | 2 | 0.84% | 1.05% | 1.26% | Q4 2015 | Q1 2016 | 2 |
| CARA | Cara Therapeutics Inc | 2 | 2 | 0.70% | 0.84% | 0.98% | Q1 2017 | Q2 2017 | 2 |
| STRO | Sutro Biopharma Inc | 2 | 2 | 0.67% | 0.80% | 0.93% | Q3 2018 | Q4 2018 | 2 |
| KNSA | Kiniksa Pharmaceutical... | 1 | 1 | 0.10% | 0.79% | 1.48% | Q2 2018 | Q1 2019 | 2 |
| SLGL | Sol-Gel Technologies Ltd | 2 | 2 | 0.62% | 0.75% | 0.88% | Q1 2018 | Q2 2018 | 2 |
| KMDA | Kamada Ltd | 1 | 1 | 0.43% | 0.61% | 0.79% | Q4 2015 | Q2 2017 | 2 |
| Intec Pharma Ltd | 1 | 1 | 0.46% | 0.55% | 0.64% | Q4 2016 | Q3 2017 | 2 | |
| RDHL | Redhill Biopharma Ltd | 1 | 1 | 0.44% | 0.51% | 0.58% | Q4 2015 | Q4 2016 | 2 |
| SCYX | SCYNEXIS Inc | 1 | 1 | 0.35% | 0.43% | 0.52% | Q4 2015 | Q2 2016 | 2 |
| AXGT | Axovant Sciences Ltd | 1 | 1 | 0.07% | 0.42% | 0.76% | Q1 2017 | Q3 2017 | 2 |
| MGTA | Magenta Therapeutics Inc | 2 | 2 | 0.31% | 0.33% | 0.34% | Q2 2018 | Q3 2018 | 2 |
| ZFGN | Zafgen Inc | 2 | 2 | 0.15% | 0.32% | 0.49% | Q4 2017 | Q1 2018 | 2 |
| ZYNE | Zynerba Pharmaceutical... | 1 | 1 | 0.21% | 0.28% | 0.34% | Q4 2015 | Q2 2016 | 2 |
| SRRA | Sierra Oncology Inc | 2 | 2 | 0.20% | 0.26% | 0.31% | Q1 2017 | Q2 2017 | 2 |
| AVEO | AVEO Pharmaceuticals Inc | 1 | 1 | 0.05% | 0.24% | 0.43% | Q2 2016 | Q3 2017 | 2 |
| BPMX | BioPharmX Corp | 1 | 1 | 0.02% | 0.21% | 0.39% | Q1 2016 | Q3 2016 | 2 |
| OBSV | ObsEva SA | 2 | 2 | 0.13% | 0.20% | 0.27% | Q1 2017 | Q2 2017 | 2 |
| MTEM | Molecular Templates Inc | 2 | 2 | 0.11% | 0.12% | 0.14% | Q2 2018 | Q3 2018 | 2 |
| VCNX | Vaccinex Inc | 2 | 2 | 0.02% | 0.02% | 0.03% | Q3 2018 | Q4 2018 | 2 |
| SPDR S&P Biotech ETF | 1 | 1 | 16.29% | 16.29% | 16.29% | Q3 2016 | Q3 2016 | 1 | |
| TEVA | Teva Pharmaceutical In... | 1 | 1 | 10.70% | 10.70% | 10.70% | Q4 2018 | Q4 2018 | 1 |
| CHRS | Coherus Biosciences Inc | 1 | 1 | 5.82% | 5.82% | 5.82% | Q2 2019 | Q2 2019 | 1 |
| VRTX | Vertex Pharmaceuticals... | 1 | 1 | 5.58% | 5.58% | 5.58% | Q1 2017 | Q1 2017 | 1 |
| KITE | Kite Pharma Inc | 1 | 1 | 4.97% | 4.97% | 4.97% | Q2 2017 | Q2 2017 | 1 |
| SNY | Sanofi | 1 | 1 | 4.87% | 4.87% | 4.87% | Q1 2016 | Q1 2016 | 1 |
| TEVA | Teva Pharmaceutical In... | 1 | 1 | 4.53% | 4.53% | 4.53% | Q3 2017 | Q3 2017 | 1 |
| AMGN | Amgen Inc | 1 | 1 | 3.95% | 3.95% | 3.95% | Q2 2016 | Q2 2016 | 1 |
| TESARO Inc | 1 | 1 | 3.94% | 3.94% | 3.94% | Q4 2016 | Q4 2016 | 1 | |
| BMY | Bristol-Myers Squibb Co | 1 | 1 | 3.34% | 3.34% | 3.34% | Q4 2017 | Q4 2017 | 1 |
| BHVN | Biohaven Pharmaceutica... | 1 | 1 | 3.14% | 3.14% | 3.14% | Q2 2019 | Q2 2019 | 1 |
| ABLX | Ablynx NV | 1 | 1 | 2.94% | 2.94% | 2.94% | Q4 2017 | Q4 2017 | 1 |
| AKAOQ | Achaogen Inc | 1 | 1 | 2.37% | 2.37% | 2.37% | Q3 2017 | Q3 2017 | 1 |
| CLCD | CoLucid Pharmaceutical... | 1 | 1 | 2.34% | 2.34% | 2.34% | Q3 2016 | Q3 2016 | 1 |
| FLXN | Flexion Therapeutics Inc | 1 | 1 | 2.15% | 2.15% | 2.15% | Q4 2017 | Q4 2017 | 1 |
| Exelixis Inc | 1 | 1 | 2.06% | 2.06% | 2.06% | Q1 2016 | Q1 2016 | 1 | |
| ACAD | ACADIA Pharmaceuticals... | 1 | 1 | 1.99% | 1.99% | 1.99% | Q3 2018 | Q3 2018 | 1 |
| ARQL | ArQule Inc | 1 | 1 | 1.88% | 1.88% | 1.88% | Q3 2018 | Q3 2018 | 1 |
| ESPR | Esperion Therapeutics Inc | 1 | 1 | 1.74% | 1.74% | 1.74% | Q2 2018 | Q2 2018 | 1 |
| SCMP | Sucampo Pharmaceutical... | 1 | 1 | 1.69% | 1.69% | 1.69% | Q4 2017 | Q4 2017 | 1 |
| ALXN | Alexion Pharmaceutical... | 1 | 1 | 1.60% | 1.60% | 1.60% | Q4 2017 | Q4 2017 | 1 |
| ITCI | Intra-Cellular Therapi... | 1 | 1 | 1.55% | 1.55% | 1.55% | Q2 2019 | Q2 2019 | 1 |
| NKTR | Nektar Therapeutics | 1 | 1 | 1.50% | 1.50% | 1.50% | Q3 2018 | Q3 2018 | 1 |
| REGN | Regeneron Pharmaceutic... | 1 | 1 | 1.48% | 1.48% | 1.48% | Q2 2019 | Q2 2019 | 1 |
| EGRX | Eagle Pharmaceuticals Inc | 1 | 1 | 1.38% | 1.38% | 1.38% | Q1 2016 | Q1 2016 | 1 |
| SUPN | Supernus Pharmaceutica... | 1 | 1 | 1.36% | 1.36% | 1.36% | Q3 2017 | Q3 2017 | 1 |
| ARWR | Arrowhead Pharmaceutic... | 1 | 1 | 1.32% | 1.32% | 1.32% | Q1 2018 | Q1 2018 | 1 |
| ABEO | Abeona Therapeutics Inc | 1 | 1 | 1.32% | 1.32% | 1.32% | Q3 2017 | Q3 2017 | 1 |
| NewLink Genetics Corp | 1 | 1 | 1.20% | 1.20% | 1.20% | Q4 2016 | Q4 2016 | 1 | |
| EDGE | Edge Therapeutics Inc | 1 | 1 | 1.19% | 1.19% | 1.19% | Q2 2016 | Q2 2016 | 1 |
| CTIC | CTI BioPharma Corp | 1 | 1 | 1.14% | 1.14% | 1.14% | Q4 2015 | Q4 2015 | 1 |
| ACHN | Achillion Pharmaceutic... | 1 | 1 | 1.12% | 1.12% | 1.12% | Q3 2018 | Q3 2018 | 1 |
| VKTX | Viking Therapeutics Inc | 1 | 1 | 1.09% | 1.09% | 1.09% | Q3 2018 | Q3 2018 | 1 |
| GILD | Gilead Sciences Inc | 1 | 1 | 1.05% | 1.05% | 1.05% | Q2 2019 | Q2 2019 | 1 |
| LLY | Eli Lilly & Co | 1 | 1 | 1.03% | 1.03% | 1.03% | Q3 2018 | Q3 2018 | 1 |
| PFE | Pfizer Inc | 1 | 1 | 1.01% | 1.01% | 1.01% | Q3 2018 | Q3 2018 | 1 |
| INSM | Insmed Inc | 1 | 1 | 0.97% | 0.97% | 0.97% | Q3 2018 | Q3 2018 | 1 |
| ATRA | Atara Biotherapeutics Inc | 1 | 1 | 0.96% | 0.96% | 0.96% | Q4 2017 | Q4 2017 | 1 |
| SPPI | Spectrum Pharmaceutica... | 1 | 1 | 0.91% | 0.91% | 0.91% | Q4 2017 | Q4 2017 | 1 |
| DRRX | Durect Corp | 1 | 1 | 0.88% | 0.88% | 0.88% | Q4 2015 | Q4 2015 | 1 |
| AXGT | Axovant Sciences Ltd | 1 | 1 | 0.86% | 0.86% | 0.86% | Q3 2016 | Q3 2016 | 1 |
| SCLN | SciClone Pharmaceutica... | 1 | 1 | 0.85% | 0.85% | 0.85% | Q4 2015 | Q4 2015 | 1 |
| RARX | Ra Pharmaceuticals Inc | 1 | 1 | 0.83% | 0.83% | 0.83% | Q2 2017 | Q2 2017 | 1 |
| AXSM | Axsome Therapeutics Inc | 1 | 1 | 0.80% | 0.80% | 0.80% | Q1 2017 | Q1 2017 | 1 |
| INFI | Infinity Pharmaceutica... | 1 | 1 | 0.79% | 0.79% | 0.79% | Q1 2016 | Q1 2016 | 1 |
| ADRO | Aduro Biotech Inc | 1 | 1 | 0.77% | 0.77% | 0.77% | Q2 2017 | Q2 2017 | 1 |
| AVDL | Avadel Pharmaceuticals... | 1 | 1 | 0.76% | 0.76% | 0.76% | Q4 2017 | Q4 2017 | 1 |
| PRGO | Perrigo Co PLC | 1 | 1 | 0.76% | 0.76% | 0.76% | Q1 2018 | Q1 2018 | 1 |
| TIG | TiGenix NV | 1 | 1 | 0.73% | 0.73% | 0.73% | Q1 2017 | Q1 2017 | 1 |
| Axovant Sciences Ltd | 1 | 1 | 0.73% | 0.73% | 0.73% | Q4 2016 | Q4 2016 | 1 | |
| CTMX | CytomX Therapeutics Inc | 1 | 1 | 0.70% | 0.70% | 0.70% | Q4 2017 | Q4 2017 | 1 |
| OPHT | Ophthotech Corp | 1 | 1 | 0.68% | 0.68% | 0.68% | Q3 2016 | Q3 2016 | 1 |
| ITEK | Inotek Pharmaceuticals... | 1 | 1 | 0.68% | 0.68% | 0.68% | Q4 2015 | Q4 2015 | 1 |
| ATNX | Athenex Inc | 1 | 1 | 0.64% | 0.64% | 0.64% | Q4 2018 | Q4 2018 | 1 |
| IOVA | Iovance Biotherapeutic... | 1 | 1 | 0.64% | 0.64% | 0.64% | Q3 2018 | Q3 2018 | 1 |
| ONTY | Oncothyreon Inc | 1 | 1 | 0.63% | 0.63% | 0.63% | Q4 2015 | Q4 2015 | 1 |
| OTIC | Otonomy Inc | 1 | 1 | 0.62% | 0.62% | 0.62% | Q4 2017 | Q4 2017 | 1 |
| INO | Inovio Pharmaceuticals... | 1 | 1 | 0.57% | 0.57% | 0.57% | Q4 2015 | Q4 2015 | 1 |
| ANAB | AnaptysBio Inc | 1 | 1 | 0.57% | 0.57% | 0.57% | Q2 2019 | Q2 2019 | 1 |
| ALRN | Aileron Therapeutics Inc | 1 | 1 | 0.55% | 0.55% | 0.55% | Q2 2017 | Q2 2017 | 1 |
| VTAE | Vitae Pharmaceuticals Inc | 1 | 1 | 0.53% | 0.53% | 0.53% | Q4 2015 | Q4 2015 | 1 |
| ANIP | ANI Pharmaceuticals Inc | 1 | 1 | 0.50% | 0.50% | 0.50% | Q4 2017 | Q4 2017 | 1 |
| GWPH | GW Pharmaceuticals PLC | 1 | 1 | 0.49% | 0.49% | 0.49% | Q4 2015 | Q4 2015 | 1 |
| SESN | Sesen Bio Inc | 1 | 1 | 0.48% | 0.48% | 0.48% | Q3 2018 | Q3 2018 | 1 |
| ADVM | Adverum Biotechnologie... | 1 | 1 | 0.48% | 0.48% | 0.48% | Q1 2018 | Q1 2018 | 1 |
| MNLO | Menlo Therapeutics Inc | 1 | 1 | 0.46% | 0.46% | 0.46% | Q1 2018 | Q1 2018 | 1 |
| DNAI | Pronai Therapeutics Inc | 1 | 1 | 0.43% | 0.43% | 0.43% | Q4 2015 | Q4 2015 | 1 |
| PPHM | Peregrine Pharmaceutic... | 1 | 1 | 0.41% | 0.41% | 0.41% | Q4 2015 | Q4 2015 | 1 |
| MACK | Merrimack Pharmaceutic... | 1 | 1 | 0.40% | 0.40% | 0.40% | Q4 2015 | Q4 2015 | 1 |
| OSMT | Osmotica Pharmaceutica... | 1 | 1 | 0.38% | 0.38% | 0.38% | Q4 2018 | Q4 2018 | 1 |
| XNPT | XenoPort Inc | 1 | 1 | 0.37% | 0.37% | 0.37% | Q1 2016 | Q1 2016 | 1 |
| AAAP | Advanced Accelerator A... | 1 | 1 | 0.33% | 0.33% | 0.33% | Q4 2015 | Q4 2015 | 1 |
| KALV | KalVista Pharmaceutica... | 1 | 1 | 0.32% | 0.32% | 0.32% | Q4 2017 | Q4 2017 | 1 |
| XENE | Xenon Pharmaceuticals Inc | 1 | 1 | 0.31% | 0.31% | 0.31% | Q1 2018 | Q1 2018 | 1 |
| Amicus Therapeutics Inc | 1 | 1 | 0.29% | 0.29% | 0.29% | Q4 2016 | Q4 2016 | 1 | |
| ALKS | Alkermes PLC | 1 | 1 | 0.28% | 0.28% | 0.28% | Q1 2017 | Q1 2017 | 1 |
| OMED | OncoMed Pharmaceutical... | 1 | 1 | 0.26% | 0.26% | 0.26% | Q3 2018 | Q3 2018 | 1 |
| SGYPQ | Synergy Pharmaceutical... | 1 | 1 | 0.24% | 0.24% | 0.24% | Q3 2018 | Q3 2018 | 1 |
| CPXX | Celator Pharmaceutical... | 1 | 1 | 0.22% | 0.22% | 0.22% | Q4 2015 | Q4 2015 | 1 |
| SVRA | Savara Inc | 1 | 1 | 0.21% | 0.21% | 0.21% | Q3 2018 | Q3 2018 | 1 |
| SBBP | Strongbridge Biopharma... | 1 | 1 | 0.21% | 0.21% | 0.21% | Q2 2017 | Q2 2017 | 1 |
| CERU | Cerulean Pharma Inc | 1 | 1 | 0.20% | 0.20% | 0.20% | Q4 2015 | Q4 2015 | 1 |
| PRQR | ProQR Therapeutics NV | 1 | 1 | 0.20% | 0.20% | 0.20% | Q3 2018 | Q3 2018 | 1 |
| FCSC | Fibrocell Science Inc | 1 | 1 | 0.19% | 0.19% | 0.19% | Q4 2015 | Q4 2015 | 1 |
| ADAP | Adaptimmune Therapeuti... | 1 | 1 | 0.19% | 0.19% | 0.19% | Q3 2018 | Q3 2018 | 1 |
| ARPO | Aerpio Pharmaceuticals... | 1 | 1 | 0.19% | 0.19% | 0.19% | Q2 2018 | Q2 2018 | 1 |
| ACAD | ACADIA Pharmaceuticals... | 1 | 1 | 0.18% | 0.18% | 0.18% | Q3 2018 | Q3 2018 | 1 |
| VSAR | Versartis Inc | 1 | 1 | 0.16% | 0.16% | 0.16% | Q2 2018 | Q2 2018 | 1 |
| TLOG | TetraLogic Pharmaceuti... | 1 | 1 | 0.16% | 0.16% | 0.16% | Q4 2015 | Q4 2015 | 1 |
| OVID | Ovid therapeutics Inc | 1 | 1 | 0.14% | 0.14% | 0.14% | Q2 2017 | Q2 2017 | 1 |
| KERX | Keryx Biopharmaceutica... | 1 | 1 | 0.13% | 0.13% | 0.13% | Q3 2018 | Q3 2018 | 1 |
| CRBP | Corbus Pharmaceuticals... | 1 | 1 | 0.10% | 0.10% | 0.10% | Q2 2018 | Q2 2018 | 1 |
| TGTX | TG Therapeutics Inc | 1 | 1 | 0.10% | 0.10% | 0.10% | Q2 2018 | Q2 2018 | 1 |
| GNVC | GenVec Inc | 1 | 1 | 0.05% | 0.05% | 0.05% | Q4 2015 | Q4 2015 | 1 |
| AVRO | Avrobio Inc | 1 | 1 | 0.04% | 0.04% | 0.04% | Q2 2018 | Q2 2018 | 1 |
| FIXX | Homology Medicines Inc | 1 | 1 | 0.04% | 0.04% | 0.04% | Q1 2018 | Q1 2018 | 1 |
| TCON | Tracon Pharmaceuticals... | 1 | 1 | 0.04% | 0.04% | 0.04% | Q4 2016 | Q4 2016 | 1 |
Download | |||||||||
The securities at the top of the list , including Insmed Inc, Global Blood Therapeutics Inc, and Shire PLC, are the highest-conviction holdings of NEXTHERA CAPITAL LP.
The conviction is calculated by counting the number of quarters a security has been reported by NEXTHERA CAPITAL LP. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that NEXTHERA CAPITAL LP owns currently or has owned in the past.